MICROBIAL CONVERSION OF ANTHRACYCLINE ANTIBIOTICS I. MICROBIAL CONVERSION OF ACLACINOMYCIN BTO ACLACINOMYCIN A

MICROBIAL CONVERSION OF ANTHRACYCLINE ANTIBIOTICS I. MICROBIAL CONVERSION OF ACLACINOMYCIN BTO ACLACINOMYCIN A Aclacinomycin X, a Novel Anthracycline Antibiotic Produced by<i>Streptomyces galilaeus</i>ATCC 31133 New anthracycline metabolites from mutant strains of Streptomyces galilaeus MA144-M1. I. Isolation and characterization of various blocked mutants. Biosynthesis of anthracycline antibiotics by Streptomyces galilaeus. II. Structure of new anthracycline antibiotics obtained by microbial glycosidation and biological activity. Antitumor anthracycline antibiotics, aclacinomycin A and analogues. II. Structural determination. Antitumor anthracycline antibiotics, aclacinomycin A and analogues. I. Taxonomy, production, isolation and physicochemical properties. New Betaclamycin and Aclarubicin Analogs Obtained by Prolonged Microbial Conversion with an Aclarubicin-negative Mutant. New Anthracycline Metabolites Produced by the Aklavinone 11-Hydroxylase Gene in Streptomyces galilaeus ATCC 31133. New anthracycline metabolites from mutant strains of Streptomyces galilaeus MA144-M1. II. Structure of 2-hydroxyaklavinone and new aklavinone glycosides. A gene cluster from Streptomyces galilaeus involved in glycosylation of aclarubicin